UBS Group
MYGN icon

UBS Group’s Myriad Genetics MYGN Stock Holding History

UBS Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-100
Closed -$1K – 8202
2020
Q1 		$1K Hold
100
– – ﹤0.01% 7780
2019
Q4 		$3K Buy
+100
New +$2.75K ﹤0.01% 7752
2015
Q1 		– Sell
-100
Closed -$3K – 9148
2014
Q4 		$3K Buy
+100
New +$3.55K ﹤0.01% 9249

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group's MYGN Position: Q2 2026 in Review

UBS Group reduced its Myriad Genetics (MYGN) stake by 58% in Q2 2026, selling an estimated $1.86M and leaving 294,346 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #5267.

UBS Group first reported a position in MYGN in Q4 2014 and has held it in 47 quarters since. The position peaked at $6.55M in Q4 2024. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • UBS Group held 294,346 shares of Myriad Genetics worth $1.68M as of Q2 2026.
  • UBS Group sold 408,821 Myriad Genetics shares in Q2 2026, an estimated $1.86M.
  • Myriad Genetics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5267 holding.
  • UBS Group first reported a position in Myriad Genetics in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Myriad Genetics position peaked at $6.55M in Q4 2024.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.